母体微嵌合保护血友病 A 患者免受抑制剂的产生。
Maternal microchimerism protects hemophilia A patients from inhibitor development.
机构信息
Department of Clinical Laboratory Medicine and.
Faculty of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
出版信息
Blood Adv. 2020 May 12;4(9):1867-1869. doi: 10.1182/bloodadvances.2020001832.
Abstract
Deleterious mutations do not necessarily lead to the incidence of inhibitors in hemophilia A patients receiving replacement therapy. Maternal chimeric cells migrated into a fetus with hemophilia A during pregnancy could induce tolerance toward FVIII.
摘要
在接受替代治疗的血友病 A 患者中，有害突变不一定导致抑制剂的发生。在怀孕期间，母体嵌合细胞迁移到患有血友病 A 的胎儿中，可诱导对 FVIII 的耐受。
相似文献
1
Maternal microchimerism protects hemophilia A patients from inhibitor development.母体微嵌合保护血友病 A 患者免受抑制剂的产生。
Blood Adv. 2020 May 12;4(9):1867-1869. doi: 10.1182/bloodadvances.2020001832.
2
3
Maternal and sibling microchimerism in twins and triplets discordant for neonatal lupus syndrome-congenital heart block.新生儿狼疮综合征-先天性心脏传导阻滞不一致的双胞胎和三胞胎中的母体和同胞微嵌合体。
Rheumatology (Oxford). 2005 Feb;44(2):187-91. doi: 10.1093/rheumatology/keh453. Epub 2004 Nov 9.
4
The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.血友病抑制剂产生的多因素病因：遗传与环境。
Semin Thromb Hemost. 2009 Nov;35(8):723-34. doi: 10.1055/s-0029-1245105. Epub 2010 Feb 18.
5
Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.儿童甲型血友病抑制剂：发展和消除的遗传和治疗相关危险因素。
Pediatr Blood Cancer. 2013;60 Suppl 1:S30-3. doi: 10.1002/pbc.24338. Epub 2012 Oct 25.
6
Frequency of fetal-maternal microchimerism: an analysis of the HLA-DRB1 gene in cord blood and maternal sample pairs.胎儿-母体微嵌合体的频率：对脐带血和母体样本对中HLA-DRB1基因的分析
J Matern Fetal Neonatal Med. 2017 Nov;30(21):2613-2619. doi: 10.1080/14767058.2016.1259308. Epub 2016 Dec 7.
7
[Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].[血友病抑制剂的研发及血友病患者的预防与管理策略]
Zhonghua Er Ke Za Zhi. 2013 Aug;51(8):631-4.
8
A total program for the patient with hemophilia. I. Medical aspects.血友病患者的全面治疗方案。一、医学方面。
Phys Ther. 1966 Dec;46(12):1268-71. doi: 10.1093/ptj/46.12.1268.
9
[Risk factors of inhibitor development among hemophilia patients revealed in a 10-year prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2)].[日本一项为期10年的前瞻性队列研究（J-HIS2，日本血友病抑制物研究2）揭示的血友病患者中抑制物形成的危险因素]
Rinsho Ketsueki. 2021;62(7):790-800. doi: 10.11406/rinketsu.62.790.
10
Higher frequency of CD4(+)CD25(high) Treg cells in hemophilia patients with factor VIII inhibitor.伴有凝血因子 VIII 抑制物的血友病患者中 CD4(+)CD25(高表达)调节性 T 细胞的频率更高。
Genet Mol Res. 2014 Mar 17;13(1):1774-81. doi: 10.4238/2014.March.17.5.
引用本文的文献
1
Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications.血友病 A 患者伴抑制物：作用机制的新见解及新的治疗意义。
Front Immunol. 2022 Dec 8;13:1019275. doi: 10.3389/fimmu.2022.1019275. eCollection 2022.
2
Savior Siblings Might Rescue Fetal Lethality But Not Adult Lymphoma in Irf2bp2-Null Mice.拯救兄妹可能挽救胎儿致死性，但不能挽救 Irf2bp2 基因敲除小鼠的成体淋巴瘤。
Front Immunol. 2022 Jul 4;13:868053. doi: 10.3389/fimmu.2022.868053. eCollection 2022.
本文引用的文献
1
Risk factors for inhibitor development in severe hemophilia a.重型血友病 A 患者抑制剂产生的风险因素。
Thromb Res. 2018 Aug;168:20-27. doi: 10.1016/j.thromres.2018.05.027. Epub 2018 May 25.
2
Thymus-Derived Regulatory T Cells Are Positively Selected on Natural Self-Antigen through Cognate Interactions of High Functional Avidity.胸腺来源的调节性 T 细胞通过高功能亲和力的同源相互作用对天然自身抗原进行阳性选择。
Immunity. 2016 May 17;44(5):1114-26. doi: 10.1016/j.immuni.2016.04.018.
3
The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.血小板衍生的FVIII在有或无预先存在的抗FVIII免疫的甲型血友病小鼠中的免疫原性。
Blood. 2016 Mar 10;127(10):1346-54. doi: 10.1182/blood-2015-08-662916. Epub 2015 Dec 14.
4
Cross-Generational Reproductive Fitness Enforced by Microchimeric Maternal Cells.微嵌合母体细胞对跨代生殖适应性的影响
Cell. 2015 Jul 30;162(3):505-15. doi: 10.1016/j.cell.2015.07.006. Epub 2015 Jul 23.
5
The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A.对凝血因子VIII合成起源的探寻及其对甲型血友病治疗策略的影响。
Haematologica. 2015 Jul;100(7):849-50. doi: 10.3324/haematol.2015.129858.
6
Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.凝血因子 VIII 的肝外来源可能有助于凝血级联反应，纠正甲型血友病小鼠的出血表型。
Haematologica. 2015 Jul;100(7):881-92. doi: 10.3324/haematol.2014.123117. Epub 2015 Apr 24.
7
FVIII inhibitors: pathogenesis and avoidance.凝血因子VIII抑制剂：发病机制与预防
Blood. 2015 Mar 26;125(13):2045-51. doi: 10.1182/blood-2014-08-535328. Epub 2015 Feb 23.
8
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.2000年至2011年英国既往未治疗的重度甲型血友病儿童中凝血因子VIII品牌与凝血因子VIII抑制剂发生率
Blood. 2014 Nov 27;124(23):3389-97. doi: 10.1182/blood-2014-07-580498. Epub 2014 Oct 22.
9
Unraveling the genetics of inhibitors in hemophilia.解析血友病抑制剂的遗传学。
Blood. 2013 Feb 21;121(8):1250-1. doi: 10.1182/blood-2012-12-472647.
10
The otherness of self: microchimerism in health and disease.自我的他性：健康与疾病中的微嵌合体。
Trends Immunol. 2012 Aug;33(8):421-7. doi: 10.1016/j.it.2012.03.002. Epub 2012 May 19.
Zotero 插件